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ABSTRACT 
Allogeneic hematopoietic stem cell transplantation (HSCT) has been presented as a 
promising immunotherapy not only against hematological malignancies but also against 
solid tumors. Different solid tumors such as renal cell, breast, colon, prostate and 
advanced primary liver cancer have been treated with HSCT at our center. Treatment 
with HSCT gives rise to an anti-tumor response so called graft-versus-tumor (GvT) 
effect that has been demonstrated as tumor regression of metastasis.  
Before transplantation, patients receive non-myeloablative conditioning also known as 
low intensity conditioning (LIC) or reduced intensity conditioning (RIC) that eradicates 
the bone marrow to a lesser extent, allowing place for the new hematopoietic stem cells 
from the donor. The presence of remaining tumor cells or mixed chimerism threatens 
the patient with disease relapse after the LIC/RIC regimen. Therefore, the GvT effect 
after LIC/RIC regimen relies on donor lymphocyte infusions (DLI), i.e. adoptive 
immunotherapy that can contribute to full donor chimerism. 
A common complication after HSCT is graft-versus-host disease (GvHD), i.e. the 
attack of the transplanted cells against the patient’s epithelial cells in the skin, bowel 
and liver. It seems that donor T lymphocytes mediate both GvHD and the GvT effect, 
since the risk for tumor recurrence is higher when donor T lymphocytes are depleted 
from the transplant. Therefore, a patient having mild acute or chronic GvHD, has a 
predictable high chance of the GvT effect. 
In paper I, we studied inflammatory and anti-inflammatory cytokines in serum using 
ELISA in four patients with metastatic renal cell and two with colon cancer. We found 
dominating TNF-α and IFN-γ levels in serum, which correlated with tumor regression. 
In paper II, we retrospectively determined the risk factors for complications in 48 
patients with solid tumors receiving LIC as compared to RIC regimen. We reported that 
engraftment and development of donor B cell chimerism occurred earlier in patients 
receiving LIC than in patients receiving RIC. The best GvT effect was demonstrated in 
patients with advanced primary liver cancer who had previously undergone liver 
transplantation. The most favorable GvT effect was found in patients who received DLI 
and developed chronic GvHD. A tendency for prolonged survival was found in patients 
receiving RIC compared to the LIC group. 
In paper III, we measured cytokine secretion using ELISpot during DLI given to four 
patients with solid tumors and four with hematological malignancies. Increased 
expression of TNF-α, IFN-γ, IL-10 and IL-12 in mononuclear cells (MNC) was found 
in patients with favorable outcome of disease response after DLI.  
In paper IV, we detected and identified tumor-reactive T lymphocytes from an HLA-
identical sibling against tumor cells from a patient with pancreatic cancer using flow-
cytometric assay of specific cell-mediated immune responses in activated whole blood 
(FASCIA). Using CDR3 size spectratyping tumor-reactive T lymphocytes could be 
distinguished from T lymphocytes activated against peripheral blood MNC from the 
patient. 
In conclusion, these findings might give a better treatment aiming at a more effective 
GvT effect. Monitoring cytokines before DLI could predict those patients who will gain 
from immunotherapy. Combining FASCIA and CDR3 size spectratyping might be a 
way to identify, isolate, in vitro expand and infuse tumor-specific T lymphocytes from 
donors in order to intensify the GvT effect.                
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1 SUMMARY 
Allogeneic hematopoietic stem cell transplantation (HSCT) has been presented as a 
promising immunotherapy not only against hematological malignancies but also against 
solid tumors. Different solid tumors such as renal cell, breast, colon, prostate and 
advanced primary liver cancer have been treated with HSCT at our center. Treatment 
with HSCT gives rise to an anti-tumor response so called graft-versus-tumor (GvT) 
effect that has been demonstrated as tumor regression of metastasis.  
Before transplantation, patients receive non-myeloablative conditioning also known as 
low intensity conditioning (LIC) or reduced intensity conditioning (RIC) that eradicates 
the bone marrow to a lesser extent, allowing place for the new hematopoietic stem cells 
from the donor. The presence of remaining tumor cells or mixed chimerism threatens 
the patient with disease relapse after the LIC/RIC regimen. Therefore, the GvT effect 
after LIC/RIC regimen relies on donor lymphocyte infusions (DLI), i.e. adoptive 
immunotherapy that can contribute to full donor chimerism. 
A common complication after HSCT is graft-versus-host disease (GvHD), i.e. the 
attack of the transplanted cells against the patient’s epithelial cells in the skin, bowel 
and liver. It seems that donor T lymphocytes mediate both GvHD and the GvT effect, 
since the risk for tumor recurrence is higher when donor T lymphocytes are depleted 
from the transplant. Therefore, a patient having mild acute or chronic GvHD, has a 
predictable high chance of the GvT effect. 
In paper I, we studied inflammatory and anti-inflammatory cytokines in serum using 
ELISA in four patients with metastatic renal cell and two with colon cancer. We found 
dominating TNF-α and IFN-γ levels in serum, which correlated with tumor regression. 
In paper II, we retrospectively determined the risk factors for complications in 48 
patients with solid tumors receiving LIC as compared to RIC regimen. We reported that 
engraftment and development of donor B cell chimerism occurred earlier in patients 
receiving LIC than in patients receiving RIC. The best GvT effect was demonstrated in 
patients with advanced primary liver cancer who had previously undergone liver 
transplantation. The most favorable GvT effect was found in patients who received DLI 
and developed chronic GvHD. A tendency for prolonged survival was found in patients 
receiving RIC compared to the LIC group. 
In paper III, we measured cytokine secretion using ELISpot during DLI given to four 
patients with solid tumors and four with hematological malignancies. Increased 
expression of TNF-α, IFN-γ, IL-10 and IL-12 in mononuclear cells (MNC) was found 
in patients with favorable outcome of disease response after DLI.  
In paper IV, we detected and identified tumor-reactive T lymphocytes from an HLA-
identical sibling against tumor cells from a patient with pancreatic cancer using flow-
cytometric assay of specific cell-mediated immune responses in activated whole blood 
(FASCIA). Using CDR3 size spectratyping tumor-reactive T lymphocytes could be 
distinguished from T lymphocytes activated against peripheral blood MNC from the 
patient. 
In conclusion, these findings might give a better treatment aiming at a more effective 
GvT effect. Monitoring cytokines before DLI could predict those patients who will gain 
from immunotherapy. Combining FASCIA and CDR3 size spectratyping might be a 
way to identify, isolate, in vitro expand and infuse tumor-specific T lymphocytes from 
donors in order to intensify the GvT effect.                
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2 INTRODUCTION 
 
2.1 IMMUNE SYSTEM 
 
The era of immunology started in 1796 when Edward Jenner inoculated cowpox, or 
vaccinia, to induce protection against human smallpox; thereby the term vaccination 
was introduced. But it took one century until Robert Koch discovered that 
microorganisms cause infectious diseases. Today, we know about four categories of 
foreign microorganisms: viruses, bacteria, pathogenic fungi and parasites. The first 
success of vaccination was achieved by Louis Pasteur in 1880, when he, with a rabies 
vaccine, cured a boy bitten by a rabid dog. In 1884 Ilja Metjnikov discovered that 
phagocytic cells, which he called macrophages, can engulf microorganisms. One 
decade later, Emil von Behring and Shibasaburo Kitasato discovered that the serum of 
animals immune to diphtheria or tetanus contained antitoxic compounds, later called 
antibodies. Today we know that the immune system is an extraordinarily complex and 
well-organized system, which consists of the innate and the adaptive immunity.1   
 
The innate immunity, also called natural or native immunity is the first line of defense 
against microbial infectious agents and reacts always in a similar fashion to the 
microbes. This immunity is non-specific and recognizes different microbial structures 
such as pathogen-associated molecular patterns, e.g. gram-negative bacterial 
lipopolysaccharide, bacterial flagellin and peptidoglycan. However, the innate system is 
able to discriminate between self and non-self, which is an important determination 
before an immune response takes place. Activation of the innate immune system 
happens immediately and does not develop an immunological memory. The 
components of the innate immunity are epithelia in the skin, gastrointestinal tract and 
respiratory tract, phagocytes such as neutrophils and macrophages, dendritic cells (DC), 
natural killer (NK) cells, cytokines, and plasma proteins, including the proteins of the 
complement system.   
 
The adaptive immunity, also called acquired immunity is initiated by specific antigens, 
which are recognized by antigen receptors on lymphocytes. This immunity creates a 
memory after exposure of an antigen and reacts more rapidly after repeated exposure to 
the same antigen. The components of the adaptive immunity are antigen presenting 
cells (APC), DC, B and T lymphocytes, which all interact with cytokines, chemokines 
and immunoglobulins (Ig) to create a specific immune response against foreign 
antigens.              
  
The innate immune system interacts with the adaptive immune system; after 
engulfment and phagocytosis of microbes and foreign antigens by macrophages or DC 
the adaptive immunity becomes activated by expression of the co-stimulatory 
molecules B7.1 (CD80) and B7.2 (CD82) on DC. The activated DC migrates to 
peripheral lymphoid organs, the lymph nodes and become mature APC. In the lymph 
nodes, protein antigens from the microbe are displayed for recognition by T 
lymphocytes. The recognition engages antigen processing on APC together with major 
histocompatibility complex (MHC) on T lymphocytes.  
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Proteins degraded in the cytosol of any nucleated cell are processed in the cytoplasm, 
displayed by class I MHC molecules and presented to CD8+ T lymphocytes, also called 
cytotoxic T lymphocytes (CTL). Extracellular proteins degraded in the endocytic 
vesicles of APC are displayed by class II MHC molecules and presented to CD4+ T 
lymphocytes, also called T helper (Th) lymphocytes. A naive T lymphocyte is activated 
when it receives two signals. The first signal is provided when the T cell receptor 
(TCR) on T lymphocytes binds to the peptide:MHC complex. The second signal or co-
stimulatory signal is provided when CD80 or CD86 on APC binds to CD28 on the T 
lymphocyte. These two signals are required for full lymphocyte activation; whereafter 
intracellular signals give raise to proliferation and differentiation of T lymphocytes.2  
 
In addition, the immune system plays an important role in defense against malignant 
diseases, by recognizing and eliminating the transformed cells.3    
    
          
2.1.1 Components of the immune system 
 
Macrophages are phagocytic cells located in different tissues in the body. After 
maturation, they leave the circulation and migrate into tissues, ready to recognize, 
ingest and destroy foreign microbes. Macrophages are found in connective tissue, in the 
submucosal layer of the gastrointestinal tract, in the lung, along certain blood vessels in 
the liver (Kupffer cells) and in the spleen. Immature DC in peripheral tissue are also 
capable for phagocytosis. When they engulf a microbe or a foreign antigen they mature 
into APC and migrate to the lymph nodes where the antigen recognition and processing 
take place.4 Neutrophils are short-lived cells in the blood but they are not present in 
healthy tissues. They also have the ability to phagocyte foreign microbes entering the 
blood stream.  
           
Natural-killer cells are capable of killing certain tumor cells without the need for prior 
immunization or activation.5, 6 NK cells are activated in response to interferon (IFN)-β, 
IFN-γ and interleukin (IL)-12 and they can serve to contain virus infections until the 
adaptive immune response is generated and specific CTL are produced in order to clear 
the infection.7, 8 NK cell killing is mediated when infected cells or tumor cells lack the 
class I MHC molecule on their surface; thereby no signal is processed by the inhibitory 
killer cell immunoglobulin-like receptors (KIR) on the NK cell. This “missing” signal 
results in the killing of the infected/tumor cell by apoptosis via perforin/granzyme B 
and Fas/Fas ligand pathways.9, 10          
 
T lymphocytes are involved in the recognition of antigens and belong to the adaptive 
immune system. The TCR on T lymphocytes is a membrane-bound specific antigen 
recognition receptor. There are two main subsets of T lymphocytes, CD4+ T or Th 
lymphocytes and CD8+ T lymphocytes or CTL. Upon activation of antigens, naive 
CD4+ Th lymphocytes can differentiate to different subsets of effector cells, type 1 Th 
(Th1) or type 2 Th lymphocytes (Th2) depending on the cytokines they produce.  
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Th1 lymphocytes stimulate phagocyte-mediated ingestion, killing of microbes and 
induce cell-mediated immunity. Th1 development is induced by IL-12 produced by 
activated DC and macrophages, and by IFN-γ produced by NK cells or by the 
responding T lymphocytes themselves (paracrine activation). Th1 lymphocytes produce 
tumor necrosis factor (TNF)-α, IFN-γ, IL-2 and also to a lesser extent IL-10. Th1 
stimulus is maintained especially by the paracrine activity of IL-2.   
   
Th2 lymphocytes stimulate phagocyte-independent, mast cell/eosinophil-dependent 
allergic inflammation and induce a humoral immunity. Th2 development is induced by 
IL-4 produced by mast cells or by the T lymphocytes themselves in the absence of IL-
12. Th2 lymphocytes produce IL-4, IL-5, IL-10 and IL-13.  
 
Another CD4+ T lymphocyte subpopulation is regulatory T (Treg) lymphocytes, 
sometimes also called type 3 Th (Th3) lymphocytes, characterized by the phenotypic 
markers CD2511 and FoxP3.12, 13 They produce IL-10 and transforming growth factor 
(TGF)-β, and are important in suppression of the immune response. Development of 
Treg lymphocytes is generated when CD4+ lymphocytes recognize self-antigens in the 
thymus or peripheral tissues; thereby they play an important role in the maintenance of 
central and peripheral tolerance.14 Treg has been found at a higher frequency in the 
peripheral blood and in the tumor microenvironment of patients with pancreas, breast 
and ovarian cancer, and may induce peripheral ignorance of tumor cells, helping 
metastatic spread of the disease.15, 16   
 
More recently, type 17 Th (Th17) lymphocytes have been described which promote 
inflammation in a number of immunological reactions. Th17 development is induced 
by IL-1, IL-6 and IL-23 produced by activated DC and macrophages. Th17 
lymphocytes produce IL-17 and IL-22. In tumor immunology, these cells have been 
found in the tumor microenvironment in patients with ovarian cancer17 as well as in 
other solid tumors, such as hepatocellular, renal cell, prostate, pancreatic and colon 
cancer.18 These cells have also been reported in the development of graft-versus-host 
disease (GvHD) after hematopoietic stem cell transplantation (HSCT) (both HSCT and 
GvHD are discussed later).19                    
 
CD8+ T lymphocytes have cytotoxic function and upon activation of antigen and co-
stimulatory molecules they differentiate to CTL that are able to kill infected cells 
expressing the antigen. CTL kill infected cells by delivery of granule proteins, such as 
granzymes and perforin, into the infected cell. CTL can also kill by Fas/Fas ligand 
pathway, thereby inducing target cell apoptosis.    
 
B lymphocytes are also involved in the adaptive immunity. The B cell receptor exists 
both as membrane-bound antigen receptor or Ig and as secreted Ig. Upon activation B 
lymphocytes mature to Ig (antibody) producing plasma or memory cells. Secreted 
antibodies are the effector molecules of the humoral immunity.  
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2.1.2 T cell receptor genes 
 
T cell receptors and B cell receptors (Ig) on lymphocytes are responsible for antigen 
recognition, as mentioned above. Lymphocytes in the body have numerous copies of a 
single antigen receptor with a unique antigen-binding site, which determines the 
antigens that the lymphocyte can bind. To generate lymphocytes with a wide range of 
antigen specificities, a complex genetic mechanism for generating highly variable (V) 
regions of the TCR and Ig has evolved. These highly variable parts are encoded in 
several gene segments, a mechanism known as gene rearrangement. The basic 
mechanism of rearrangement for the TCR and Ig genes is common but in this thesis 
rearrangement of TCR is highlighted.  
 
The TCR consists of one α chain (TCRα) and one β chain (TCRβ), and each chain has a 
V region and a constant (C) region. The TCRα locus contains V and J gene segments 
(Vα and Jα), whereas the TCRβ locus contains V, D and J gene segments (Vβ, Dβ and 
Jβ). The TCR gene rearrangement takes place in the thymus.    
The TCR rearrangement mechanism is guided by conserved noncoding DNA 
sequences that flank the gene segments encoding the V region. These sequences are 
called recombination signal sequence (RSS) and consist of a conserved block of seven 
nucleotides (heptamer), which is always contiguous with the coding sequence followed 
by a nonconserved region (spacer) of 12 or 23 nucleotides, which is followed by a 
second conserved block of nine nucleotides (nonamer). A gene segment flanked by an 
RSS with a 12-base pair (bp) spacer can only be joined by a RSS with a 23-bp spacer. 
This is known as the 12/23 rule and makes sure that the gene segments are joined in the 
correct order.20 The recombination process is completed when recombination-activating 
genes (RAG)-1 and RAG-2 together with several DNA-modifying proteins are 
assembled with the 12-bp spaced and 23-bp spaced RSS.21  
The antigen-binding site of the V region of the TCR is formed by the complementarity-
determining regions (CDR) 1, 2 and 3. All three CDR are expressed on both TCRα and 
TCRβ. CDR1 and CDR2 loops are less variable and contact the MHC component of 
the ligand, whereas CDR3 is a hypervariable loop which contact the unique peptide 
component.22 The TCR rearrangement of TCRα and TCRβ chains is demonstrated in 
Figure 1.    
                    
             
2.2 CYTOKINES 
 
Cytokines are polypeptide growth factors that regulate the growth, differentiation and 
activation of various cell types. They can be either secreted or membrane-bound. On 
the target cells, cytokines bind to its receptors, and activate downstream signaling 
events that result in the required biological response.23 Cytokines are involved in many 
aspects of immunity and inflammation, including innate immunity, adaptive immunity, 
e.g. antigen presentation, bone marrow differentiation, cellular recruitment and 
activation, and adhesion molecule expression. Which cytokines are produced due to an 
immune response, depends on whether the response is cytotoxic, humoral, cell-
mediated or allergic.24 The cytokines examined in paper I and III are highlighted, as 
follows: TNF-α, IFN-γ, IL-4, IL-10, IL-12, IL-13 and TGF-β.  
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Figure 1. T cell receptor rearrangement of α and β TCR chains. Reprinted with permission from 
Janeway et al editors 2005.    
 
 
TNF-α is involved in systemic inflammation and is a member of a group of cytokines 
that stimulate the acute phase reaction. TNF-α is produced by activated lymphocytes, 
NK cells, macrophages, neutrophils, endothelial cells and mast cells. As mentioned 
above, in adaptive immunity, TNF-α is produced by Th1 lymphocytes. The primary 
role of TNF-α is regulation of different immune cells. TNF-α is also able to induce anti-
tumor immunity by either applying cytotoxicity directly on tumor cells or by 
stimulating anti-tumor response via apoptosis.  
 
Even though TNF-α is a potent activator of immune cells, interest for potential 
immunotherapeutic value of this cytokine to treat cancer has been moderated by its 
severe side effects. TNF-α is responsible for the severe cachexia that occurs in cancer 
and chronic infections.25 Furthermore, TNF-α induces vascular leakage and is the 
primary endogenous mediator of toxic shock and sepsis.26 These severe inflammatory 
reactions lead to fever and tissue destruction with endothelial damage. Acute treatment 
with neutralizing anti-TNF-α antibodies has reversed toxic shock and late organ failure 
in patients surviving 28 days after septic shock.27 Treatment with anti-TNF-α 
antibodies has been evoked as an effective therapy for autoimmune diseases such as 
rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease.28-30   
In the context of allogeneic HSCT, TNF-α has been recognized as an important 
inflammatory cytokine of the ‘cytokine storm’, which is a relevant mediator in the 
pathogenesis of GvHD.31  
 
In murine studies, blockade of TNF-α with anti-TNF-α antibodies or by using TNF-α 
receptor-deficient recipients has resulted in diminished GvHD and graft-versus-
leukemia effect (GvL) (discussed later).32-35 Furthermore, murine donor T cell-derived 
TNF-α has been shown to contribute to GvHD and GvL effect.36  
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In human studies, patients with acute GvHD have been reported with elevated TNF-α 
levels in serum37-40 and clinical trials have shown recovery of GvHD during treatment 
with anti-TNF-α antibodies.41, 42   
 
IFN-γ plays an important role in the innate and adaptive immunity against viral and 
intracellular bacterial infections. IFN-γ is produced predominantly by T lymphocytes, 
NK cells and natural killer T (NKT) cells and to a lesser extent by DC and 
macrophages. As mentioned above, in adaptive immunity, IFN-γ is produced by Th1 
lymphocytes. The importance of IFN-γ in the immune system derives from its 
immunostimulatory and immunomodulatory effects. It stimulates NK cells for 
phagocytosis as well as mediates increased expression of class I and II MHC 
molecules. IFN-γ is also able to induce anti-tumor immunity by applying cytotoxicity 
directly on tumor cells.  
In murine studies, double-knockout mice lacking T and B lymphocytes and a 
transcription factor required for IFN-γ signaling, spontaneously developed 
adenocarcinomas of the colon, breast and lung.43 Mice deficient in cytokines IL-12 an 
IL-23, cytokines that stimulate IFN-γ production, were more sensitive to carcinogens 
and have shown enhanced tumor development as compared with normal mice.44  
In human studies, enhanced production of IFN-γ has been found in T lymphocyte 
clones isolated from patients with GvHD.45 In the study by Remberger et al, higher 
levels of IFN-γ in serum was found in patients who developed acute GvHD grade II-IV 
than in those with no or mild GvHD.39 IFN-γ has reported to contribute to the graft-
versus-tumor effect (GvT) (discussed later), where it was produced in CD8+ T 
lymphocytes in patients with renal cell cancer.46  
 
IL-4 plays an important role in humoral immunity, specifically in the development of 
allergic immunity. IL-4 is produced by Th2 lymphocytes, mast cells, eosinophils and 
basophils. As mentioned above, IL-4 induces differentiation of naive Th lymphocytes 
to Th2 lymphocytes. Upon activation by IL-4, Th2 lymphocytes produce additional IL-
4. This cytokine induces B lymphocyte class switching from IgM to IgE. Increased 
production of IL-4 has been associated with allergies.47  
In murine models, T lymphocytes that had been experimentally manipulated to produce 
IL-4 and IL-10 were shown to inhibit development of acute GvHD.48, 49 
In human studies, one study has reported increased IL-4 producing cells in patients with 
acute GvHD as compared to patients without GvHD50, whereas another study showed 
no difference51, and a third study showed decreased IL-4 producing cells in patients 
with acute GvHD.52 
 
IL-10 inhibits activation and effector function of T lymphocytes, monocytes and 
macrophages. IL-10 is produced by both Th1 and Th2 lymphocytes, CTL, B 
lymphocytes and mast cells. The principal function of IL-10 is to limit and terminate 
inflammatory responses. This is the case, when IL-10 inhibits cytokines production, 
such as IFN-γ, IL-2 and TNF-α, and proliferation of Th1 lymphocytes by down-
regulating class II MHC molecules and the co-stimulatory molecule B7.  
In contrast, IL-10 has stimulatory effects on CD8+ T lymphocytes and induces their 
recruitment, cytotoxic activity and proliferation.53-56             
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In murine tumor cell lines, IL-10 suppressed T lymphocyte-mediated immunity by 
down-regulating class I MHC on tumor cells.57 In mice models of GvHD, 
administration of IL-10 after transplantation resulted in lethal outcome with increased 
mortality.58-60  
In human studies, IL-10 was present in large amounts in tumor biopsies from patients 
with ovarian cancer.61 Furthermore, increased IL-10 levels prior HSCT were correlated 
with lower incidence of GvHD and improved survival.62-64 In other studies, high levels 
of IL-10 after HSCT indicated a higher incidence of GvHD39, 65 and a poor prognosis 
for survival.66   
 
IL-12 is important in the induction of Th1 responses, in activation of NK cells and IFN-
γ production. IL-12 is produced by DC, macrophages and monocytes. As mentioned 
above, it is involved in the differentiation of naive Th lymphocytes into Th1 
lymphocytes. IL-12 mediates enhancement of the cytotoxic activity of NK cells and 
CTL. It is known as a factor, which can stimulate the growth and function of T 
lymphocytes. IL-12 stimulates the production of Th1 cytokines, including IFN-γ and 
TNF-α and suppresses the Th2 cytokines, such as IL-4 and IL-13.          
In murine studies, it was shown that IL-12 restores the ability of CD4+ CD25- T 
lymphocytes to proliferate and express activation markers during co-culture with 
Treg.67 IL-12 has been reported to play an important role in acute GvHD68, 69 and it also 
preserves the GvL effect.70, 71 
Also in human studies, high levels of IL-12 in plasma have been associated with the 
development of acute GvHD grade II-IV72 and with the GvL effect without increasing 
the risk for GvHD.73  
 
IL-13 has very similar features to IL-4, thus it also has important role in humoral 
immunity. As IL-4, IL-13 is produced by Th2 lymphocytes, mast cells, eosinophils and 
basophils but can also be produced by DC and NK cells.  
In murine studies, IL-13 has been reported to down-regulate anti-tumor responses to 
allow tumor growth. This anti-tumor response appeared when NKT cells were induced 
by tumors to secrete IL-13, thereby suppressing CTL responses against the tumor.74    
In human studies, development of acute GvHD grade III was associated with high 
levels of IL-13 produced by donor T lymphocytes prior to HSCT.75    
 
TGF-β is an immunosuppressive cytokine and inhibits effector function of both innate 
and adaptive immune cells. TGF-β is produced by monocytes, platelets, some T 
lymphocytes, chondrocytes, osteocytes, fibroblasts and tumor cells. In tumor 
immunology, TGF-β has been reported to promote cancer metastasis by enhancing 
tumor cell invasion and by inhibiting function of effector immune cells.76, 77 These 
findings have encouraged scientists to target TGF-β and its signalling pathway as 
immunotherapy against different cancer diseases.           
In murine studies, combination of a TGF-β monoclonal antibody and a vaccine resulted 
in the inhibition of tumor growth that was mediated by increased number and activity 
of CD8+ T lymphocytes.78-80   
In human studies, elevated levels of TGF-β in serum were associated with disease 
progression in patients with colorectal cancer81, 82 and with reduced amount of 
circulating DC.83 Furthermore, elevated TGF-β in plasma was reported in patients with 
breast84, hepatocellular85, 86, and lung cancer.87 
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2.3 ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION 
 
Allogeneic HSCT is transplantation of adult hematopoietic stem cells from the bone 
marrow or peripheral blood to a patient from a healthy donor. The first clinical studies 
on allogeneic bone marrow transplantation (BMT) in humans were performed in 1957 
by Edward Donnal Thomas and colleagues.88 For the first time it was shown that 
relatively large amounts of bone marrow could be infused to patients when bone 
fragments and fat were removed. However, the results from these early studies were 
poor. The era of modern allogeneic BMT started after the discovery of the MHC and 
the human leukocyte antigen (HLA).89, 90 In 1972, it had become evident that allogeneic 
BMT could cure leukemia, severe aplastic anemia and severe combined 
immunodeficiency.91, 92 In 1975, Thomas et al reported results on BMT with HLA-
identical sibling donors.93, 94 In Sweden, the first allogeneic BMT was performed at our 
hospital in 1977.95 In 1979, it was reported that patients with leukemia who developed 
GvHD had a decreased risk of relapse compared to patients without GvHD; thereby the 
GvL effect was discovered.96 In 1980, the first allogeneic BMT was performed with a 
matched unrelated donor (MUD).97 Today, the majority of patients who lack an HLA-
identical sibling donor will find a suitable MUD among more than fourteen million 
donors and four hundred thousand cord blood units (Bone Marrow Donors Worldwide 
2010).     
 
 
2.4 ALLOGENEIC HSCT FOR SOLID TUMORS 
       
The anti-tumor potential of the GvL effect in patients with hematological malignancies 
provided the basis to select solid tumor patients that could benefit by a GvT effect 
following allogeneic HSCT. The existence of a GvT effect has been shown in mice 
with lymphosarcomas98 and mammary adenocarcinoma99, where development of 
spontaneous tumors could be protected by HSCT using either MHC antigen matched98 
or mismatched donor.99 In 1996, the first evidence of a possible allogeneic GvT effect 
in patients with metastatic breast carcinoma undergoing allogeneic HSCT with 
myeloablative conditioning was reported.100, 101 In one of these reports, the GvT effect 
was suggested due to regression of a metastatic breast carcinoma lesion in a patient 
receiving HSCT for relapsed acute myeloid leukemia (AML).100 In the other report, the 
GvT effect was supported when regression of liver metastasis was demonstrated 
together with severe acute GvHD in a patient transplanted for metastatic breast 
carcinoma.101 These reports were followed by a report from a single institution of 10 
patients with metastatic breast carcinoma treated with myeloablative conditioning 
followed by allogeneic HSCT.102 The first clinical evidence of donor immune-mediated 
antitumor effect was demonstrated in this study, where one patient had complete 
regression and five patients experienced partial responses of metastases. However, 
enthusiasm for this immunotherapy decreased by fatal toxicities associated with the 
transplantation procedure.  
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The outlook on using the GvT effect against solid tumors improved again after the 
introduction of non-myeloablative conditioning (discussed later). Non-myeloablative 
conditioning was introduced first in patients with hematological malignancies in order 
to reduce transplantation-related mortality and to enable transplantation in older 
patients or those with organ impairment, who could not tolerate myeloablative 
therapy.103-107 The first argument for non-myeloablative conditioning for solid tumors 
was that this conditioning could also be safer for elderly patients, as it has been the case 
for the older patients with hematological malignancies. Another argument for non-
myeloablative conditioning was that chemotherapy already had failed in some solid 
tumors and conditioning therefore only was needed to prevent rejection of stem cells 
from the donor.  
 
Already in 1928 spontaneous regression of metastasis was reported in a patient with 
metastatic renal cell carcinoma, thereby realizing that the immune system could control 
tumor growth.108 The first solid tumor to be treated with non-myeloablative 
conditioning was metastatic renal cell carcinoma motivated by previous studies on 
renal cancer cell’s susceptibility to immune response in vitro and in vivo.109-111  
In 1999, Childs et al reported the first allogeneic GvT effect with complete regression 
of metastases after non-myeloablative conditioning in a patient with metastatic renal 
cell carcinoma.112 One year later, this group reported a series of 19 patients with 
metastatic renal cell carcinoma who underwent allogeneic HSCT.113 Three patients had 
complete response and remained in remission 27, 25 and 16 months after HSCT. In 
addition, seven patients had partial response. In Sweden at our center and hospital, the 
first allogeneic HSCT with non-myeloablative conditioning was performed in August 
1999 in a patient with metastatic colon carcinoma. Since the first report by Childs et al, 
several studies have been performed on allogeneic HSCT in patients with renal cell114-
126, breast115, 117, 118, 120, 127-130, colon117, 131-134, ovarian120, 135-137, prostate120, advanced 
primary liver138 and pancreatic cancer.139-142 The outcome and results on tumor 
response of these studies mentioned above will be highlighted in more detail in the 
section describing the GvT effect.                
 
During the recent years, the use of allogeneic HSCT for solid tumors has been 
decreasing. This fact can be explained by a remaining high transplantation-related 
mortality and poor survival rates due to high tumor burden before transplantation, 
different conditioning types and immunosuppression strategies. Furthermore, 
development and approval of new therapeutic drugs against tyrosine protein kinases 
and kinase enzymes, such as sorafenib, sunitinib, temsirolimus and everolimus have 
also contributed to reduction in allogeneic HSCT application. Still, worldwide pilot 
studies on allogeneic HSCT with clinical observations of GvT effect found prolonged 
survival compared to conventional anticancer therapy.      
 
 
2.4.1 Conditioning 
 
Before transplantation, the patients receive a preparative regimen, so called 
conditioning that abolishes the bone marrow from malignant cells, allowing place for 
the new immune system from the donor, thereby providing immunosuppression to 
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prevent graft rejection. In patients with malignant diseases, it is important that the 
conditioning is as intensive as possible. Therefore, myeloablative conditioning is 
applied in these patients, where the conditioning consists of high doses of 
chemotherapy with or without irradiation. This conditioning eradicates as many as 
possible of the malignant cells, diminishes the tumor burden and prevents relapse of the 
disease. One commonly used myeloablative conditioning for patients with 
hematological malignancies is cyclophosphamide (Cy) followed by total body 
irradiation (TBI), 10 Gray (Gy) given at one session.94, 143 To decrease the toxicity of 
TBI and to allow a higher total dose of irradiation, fractionated irradiation is given 
today during a longer time period with a total dose of 11 to 15 Gy.144 An alternative to 
irradiation is the use of busulphan (Bu), followed Cy in patients with AML and 
children.145-149 
 
Non-myeloablative conditioning also known as low intensity conditioning or reduced 
intensity conditioning (RIC) has been developed in order to reduce transplantation-
related mortality for patients who could not tolerate a myeloablative regimen due to 
high age or organ dysfunction.104 Thus, the purpose of RIC is not to eradicate all 
malignant cells but to create immunosuppression in order to avoid graft rejection. The 
RIC regimen does eradicate the patient’s hematopoiesis but at the time of neutrophil 
engraftment both donor and patient lymphoid and myeloid cells are detectable, so 
called mixed chimerism.106 Thus, after RIC regimen followed by allogeneic HSCT, the 
presence of remaining leukemic or tumor cells or mixed chimerism threatens the 
patient with disease relapse. Therefore, the GvT effect after RIC relies on donor 
lymphocyte infusions (DLI), i.e. adoptive immunotherapy that can contribute to full 
donor chimerism as follows myeloablative conditioning. The low intensity conditioning 
consists of 2 Gy TBI together with fludarabine (Flu).104, 150 There are several RIC 
regimens in use consisting of Flu together with Cy, Bu and melphalan for patients with 
hematological malignancies and solid tumors.104, 151  
At our center, Center for Allogeneic Stem Cell Transplantation at Karolinska 
University Hospital, Huddinge, we used low intensity conditioning between 1999 and 
until May 2001, thereafter until today RIC was used with Flu and Cy for patients with 
solid tumors.  
                     
 
2.4.2 Stem cell source 
 
Initially, hematopoietic stem cells from the bone marrow were used for allogeneic 
transplantation. Hematopoietic stem cells are characterized by the expression of CD34 
on their surface. Their abundance is 1-2 % in the bone marrow and 0.2% in the 
peripheral blood.152 Being pluripotent cells, they can expand and mature into different 
types of blood cells. Hematopoietic stem cells from bone marrow are obtained from the 
donor by aspiration from the posterior iliac crest under general or spinal anesthesia.94  
 
Since the late 1970s, it is possible to mobilize CD34+ hematopoietic stem cells to the 
peripheral blood by administration of granulocyte colony stimulating factor (G-CSF) or 
granulocyte/macrophage colony stimulating factor (GM-CSF) to the donor.  
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Administration of G-CSF results in a graft of three or four times more CD34+ cells and 
one-log higher T and NK cell dose after leukapheresis. Fear of increased risk for acute 
GvHD due to increased number of T lymphocytes compared to the bone marrow graft, 
delayed the use of peripheral blood as source of stem cells for allogeneic HSCT until 
the 1990s. However, later studies have shown that G-CSF-mobilized peripheral stem 
cells result in a faster engraftment of neutrophils and platelets153, 154 than those from 
marrow without increasing the risk for acute GvHD.155, 156 The use of peripheral stem 
cells compared to bone marrow for allogeneic HSCT, is similar regarding the incidence 
of acute GvHD, relapse, transplantation-related mortality and survival. However, 
increased occurrence of chronic GvHD has been reported in association with the use of 
peripheral stem cells.157, 158  
At our center, all solid tumor patients (except two with advanced primary liver cancer) 
were transplanted with peripheral blood stem cells.  
 
The third stem cell source is the use of hematopoietic stem cells from umbilical cord 
blood. Umbilical cord blood contains a higher amount of hematopoietic stem cells and 
progenitor cells but the total number of CD34+ cells is 1-2 log fewer compared with 
bone marrow and peripheral stem cells.159 Unfortunately, the limited volume of cord 
blood is associated with a slower engraftment and an increased risk for graft 
rejection.160, 161 However, stem cells from cord blood are more tolerant to one or two 
HLA-antigen mismatches and to overcome the cell dose limitation, transplantation of 
two cord blood units for adult patients was introduced recently.162, 163       
               
 
2.4.3 Immunosuppression 
 
Immunosuppressive treatment is given after allogeneic HSCT to prevent graft rejection 
and severe acute GvHD. The treatment consists of different drugs, and the length and 
the intensity of the treatment depends on the underlying disease, the choice of donor, 
the conditioning type and the severity of acute GvHD. Today, the most common 
protocol in use is combination of cyclosporine-A (CsA) and methotrexate (MTX).164, 165 
Other drugs used in combinations are mycophenolate mofetil (MMF)166, tacrolimus167, 
168 and sirolimus.167, 169 Another approach to decrease the incidence of GvHD, is 
depletion of T lymphocytes from the graft or in vivo with anti-T lymphocyte antibodies, 
like OKT-3 and ATG. The regimens reduce the occurrence of acute GvHD but increase 
the incidence of graft rejection and relapse.170-172  
 
At our center, CsA in combination with MMF were used during the time of low 
intensity conditioning for patients with solid tumors, whereas CsA together with MTX 
is used today for patients who receive RIC. Patients with advanced primary liver cancer 
who underwent combined orthotopic liver transplantation and allogeneic HSCT, at our 
center, continued to receive the same immunosuppression for HSCT as for the liver 
transplantation, in order to protect against rejection of the liver graft.138 This 
immunosuppression consists of either CsA or tacrolimus in combination with steroids. 
After allogeneic HSCT, CsA or tacrolimus is combined with MMF or MTX.      
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2.4.4 Graft rejection  
 
Graft rejection or graft failure occurs when immunocompetent cells remain in the 
patient despite the conditioning given and induce rejection of the transplanted cells.  
With myeloablative conditioning, the incidence of graft rejection is around 2% if an 
HLA-identical sibling donor is used, and less than 5% with a MUD.173, 174 The use of 
RIC protocols and T cell depletion increases the incidence of graft rejection (relative 
risk 9.29).172     
 
 
2.4.5 Graft-versus-host disease 
 
A common complication after allogeneic HSCT is GvHD, i.e. the attack of the 
transplanted cells from the donor against the patient’s epithelial cells in the skin, bowel, 
liver and lung. Clinical manifestations of GvHD depend on the degree of donor/patient 
histocompatibility and graft alloreactivity to major host antigens. The incidence of 
GvHD can be as high as 85% in patients receiving allogeneic HSCT, depending on the 
type of donor and the degree of HLA-matching.165, 175-177 The severity of GvHD can be 
reduced by well matched HLA-antigens between patient and donor, thereby also 
accelerate engraftment.178 Despite full match of HLA between patient and donor, 
GvHD may still develop due to differences in minor histocompatibility antigens 
(mHag).179 Studying the pathogenesis of GvHD, it was shown that infiltrating donor T 
lymphocytes play an important role in this mechanism.180 Thus, donor T lymphocytes 
mediate both GvHD and the GvT effect, therefore the main goal in this field is to 
design methods where cells responsible for GvHD can be distinguished from those 
cells that exert the GvT effect.  
 
GvHD exists in two forms, as acute and as chronic. Acute GvHD often occurs during 
the first 100 days after allogeneic HSCT or after administration of DLI. However, 
patients who have received RIC may develop acute GvHD later than three months. 
Acute GvHD involves tissue injury in the skin, liver and intestinal mucosa.181 The 
severity of acute GvHD is graded between 0 and IV.182 Grade 0 means absence of acute 
GvHD, grade I includes skin rash of less than 50% of the body surface, grade II 
involves skin rash on more than 50% of the body surface and/or mild liver involvement 
and/or mild diarrhea. Acute GvHD grade III affects the liver and/or gut more severe 
and grade IV includes erythroderma with bullous formation or severe liver disease with 
ascites and high serum levels of bilirubin or bowel inflammation with massive diarrhea 
with or without hemorrhages and ileus.183, 184 The pathophysiology of acute GvHD is 
divided in three steps.  
  
The first phase of acute GvHD occurs during the conditioning treatment before the 
donor cells are infused. Tissue damage occurs caused by the conditioning regimen, the 
underlying disease and infections. The damaged tissue initiates an immune response by 
secreting cytokines, upregulating adhesion molecules and activating DC. During this 
phase, the most commonly inflammatory cytokines are TNF-α and IL-1 secreted by 
activated DC.185 These inflammatory cytokines increases the expression of adhesion 
molecules and co-stimulatory molecules.  
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In the second phase, after infusion of the graft, presentation of host antigens to donor T 
lymphocytes occurs in the lymph nodes, thereby activation of donor T lymphocytes are 
induced. Subsequently, the activation of donor T lymphocytes stimulates first 
proliferation and finally differentiation into effector T lymphocytes. The inflammatory 
cytokines involved in this phase are IL-2 and IFN-γ.186 IL-2 induces clonal expansion 
of activated T lymphocytes and their differentiation into CTL. IFN-γ, together with IL-
2, induces further T lymphocyte expansion and induces CTL and NK cell responses. 
 
In the third phase, inflammation and more tissue damage are caused by secretion of 
inflammatory cytokines and effector T lymphocytes. Cell-mediated killing is induced 
by the perforin/granzyme B and Fas/Fas ligand cytolytic pathways, NK cells and the 
release of nitric oxide.187 This process continues with more inflammation and tissue 
damage, thereby triggering new activated donor T lymphocytes at the inflammation site 
and keeps the GvHD ongoing. 
 
The mechanism of chronic GvHD is less well studied and understood than acute 
GvHD. However, it has been shown that chronic GvHD develops due to the presence 
of alloreactive donor T lymphocytes.188 Chronic GvHD occurs beyond three months 
and it can reappear after previously determined acute GvHD but also without. The 
clinical manifestation of chronic GvHD is different from that of acute GvHD. Its 
symptoms resemble those of autoimmune conditions such as keratoconjuctivitis, 
dermatitis, liver dysfunction and immunodeficiency.189 Chronic GvHD is graded as 
limited or extensive.190  
 
Treatment of acute and chronic GvHD consists of high doses of steroids, CsA, or anti-T 
lymphocyte antibodies, like OKT-3 and ATG, IL-2 receptor antibodies, oral psoralen 
combined with extracorporal ultraviolet light A (PUVA).191, 192 Other treatments have 
also been reported with 1 Gy of total lymphoid irradiation and anti-B lymphocyte 
antibodies.193, 194          
      
 
2.4.6 Infections 
 
Infections are common after allogeneic HSCT due to immature immune system in the 
recipient followed by conditioning regimen and additional immunosuppressive 
treatments after transplantation in order to prevent GvHD. The abundance of different 
pathogens depends on the phase of the transplantation process. 
 
During the pre-engraftment phase or neutropenic period from day 0-30 after HSCT, 
gram-positive bacteria of the skin and mouth are responsible for Bacteremia.195 Gram-
negative infections of the gastrointestinal tract are not as common today as they were 
earlier due to successful prophylaxis and administration of broad-spectrum 
antibiotics.196 Regarding viral infections, reactivation of herpes simplex virus is most 
common during this phase and for seropositive patients antiviral prophylaxis is 
given.197, 198 Among fungal infections oro-esophageal candida is most common but 
aspergillus and candida can also cause invasive infections.199 
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The post-engraftment phase lasts until day 100 after transplantation and during this 
period cellular immunity is slowly recovering. Cytomegalovirus (CMV) reactivation is 
most prevalent during this phase and is often correlated to GvHD.200  
The risk of fatal outcomes from CMV disease has been reduced in the past due to the 
use of CMV prophylaxis and pre-emptive treatment based on sensitive 
qualitative/quantitative polymerase chain reaction (PCR)-based detection assays in 
order to monitor the viral load.201-204 Prophylactic treatment is administered to prevent 
opportunistic infections.205 
 
The late period starts beyond 100 days after transplantation and during this period the 
cellular and humoral immunity is not fully recovered. Reactivation of CMV, herpes 
simplex virus and varicella zoster virus (VZV) are common, especially in patients with 
chronic GvHD206, whereas bacterial infections are less common.  
        
 
2.4.7 Donor lymphocyte infusion 
 
DLI has been developed as an adoptive immunotherapy against relapse of the 
underlying disease for patients with hematological malignancies who received 
myeloablative conditioning followed by allogeneic HSCT. The allogeneic 
immunotherapeutic effect in humans was already noticed in 1979, when the incidence 
of GvHD was found to be associated with lower risk of relapse.96 Later it was 
demonstrated that patients receiving graft from a twin sibling were at higher risk of 
relapse when compared to HLA-matched sibling donors.207 The observation that donor 
T lymphocytes mediate both GvHD and the GvT effect was confirmed when depletion 
of T lymphocytes from the graft with an aim to prevent GvHD, increased the risk of 
relapse.172 These earlier findings confirmed the notion that donor T lymphocytes are the 
main effector cells on exerting the allogeneic GvT effect. 
 
The evidence that DLI has the potential to eradicate leukemic cells was already 
reported from the start suggesting a potent GvL effect in patients with chronic myeloid 
leukemia (CML).208 However, the GvL effect was less successful in patients with acute 
leukemias and other malignancies.209-213 The mechanism behind the promising 
immunological response to DLI in CML compared to acute leukemias is unknown. One 
suggestion is the slower progress of CML compared to the aggressive tumor 
development of acute leukemias. Another is the required time of DLI response (2-3 
months after administration) that allows the development of chronic GvHD in patients 
with CML. However, early administration of DLI and monitoring of minimal residual 
disease in patients with acute leukemias have given better GvL effect.214 
 
Although administration of DLI improves the GvL/GvT effect, it may also induce fatal 
GvHD. The severity of GvHD can be reduced if DLI is administered in escalating 
doses. This was reported in patients with CML, where the GvL effect was delayed with 
a time span of 6-12 months.215 However, the approach of administration of DLI in 
escalating doses is used in patients with acute leukemias and solid tumors.  
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After RIC regimen, DLI has been used in another approach, namely to convert mixed 
chimerism to full donor chimerism in patients with hematological malignancies216-219 
and solid tumors.113, 114, 116, 117, 128, 129, 134, 140, 141 In studies performed on patients with 
solid tumors, the indication for DLI was often tumor progression with mixed chimerism 
or without.     
          
Tumor response or prolonged survival after administration of DLI was demonstrated in 
patients with metastatic renal cell126, 220, colon220 and ovarian cancer.136 In the first 
study of Barkholt et al, 111-Indium labeled donor lymphocytes were infused into the 
hepatic artery of patients with renal cell or colon cancer. The donor lymphocytes were 
observed to home to metastases in the liver supporting the clinical response when one 
patient with renal cell and one with colon cancer showed stable size and number of 
metastases for 5 and 21 months, respectively.220 In the second study by Barkholt et al, 
124 patients with renal cell cancer from 21 European centers who had received DLI 
and developed chronic GvHD had the best overall survival (70% at 2-years).126 DLI 
seemed to promote GvHD and control disease progression in one out of two patients 
with ovarian cancer.136 
           
 
2.4.8 Graft-versus-tumor effect 
 
Early clinical observations on tumor response suggesting a possible GvT effect resulted 
in immunotherapies with IL-2 and IFN-α, and adoptive immunotherapy with 
lymphokine-activated killer cells (LAK) or tumor-infiltrating lymphocytes (TIL) in 
autologous settings.221-224 Furthermore, it was shown that TIL recognized melanoma-
associated antigens and these lymphocytes could infiltrate the tumors and could grow in 
vitro in medium containing IL-2.225, 226 Later, ex-vivo selected and expanded autologous 
lymphocytes were infused in patients with metastatic melanoma after lymphodepleting 
therapy demonstrating a response rate between 51% and 72%.227, 228 However, patients 
with metastatic melanoma did not benefit from the GvT effect in the allogeneic 
setting.229  
 
In the allogeneic setting, one approach to identify the GvT effect is the isolation of 
donor CTL that have the ability to kill leukemic or tumor cells from the patient with or 
without GvHD. Thus, one target peptide epitopes for CTL are mHag expressed on 
hematopoietic, epithelial or malignant hematopoietic cells. CTL specific for the mHag 
called HA-1 and HA-2 on hematopoietic cells induced remission in patients with CML 
and multiple myeloma.230 Furthermore, CTL specific for HA-1, HA-3 and HA-8 were 
isolated from patients with renal cell cancer, who showed partial tumor responses or 
stable diseases.123 However, it seems that infusion of mHag-specific T lymphocytes 
results in poor survival of the infused cells231, which may imply that these lymphocytes 
never reach the tumor environment.  
 
Another target peptide epitopes for CTL are tumor-associated antigens (TAA) 
expressed on tumor cells. CTL specific for Wilms’ tumor antigen 1 were detectable in 
patients with acute lymphoblastic leukemia with favorable tumor responses.232  
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In patients with colorectal cancer, carcinoembryonic antigen (CEA)-specific CTL were 
detectable with the onset of GvHD.133 In one patient CEA-specific CTL were 
associated with decreased CEA levels in serum and partial response of the tumor. From 
our group prostate-specific CTL were reported in a patient with prostate cancer 
associated with clinical remission.233 Recently, Takahashi et al detected donor-derived 
CTL from a patient with renal cell cancer after allogeneic HSCT and identified the 
target antigen of renal cell cancer-specific CTL.234 The target antigen was derived from 
human endogenous retrovirus type E and was selectively expressed in renal cell cancer 
cell lines and fresh renal cell cancer tissue but not in normal kidney or other tissues. 
Furthermore, one in vitro study showed superior renal cell cancer-reactive CTL 
responses of HLA-matched allogeneic T lymphocytes compared to autologous T 
cells.235 These results support the specific reactivity of allogeneic T lymphocytes 
against renal cell cancer. However, the lack of identified TAA restricts the use of 
adoptive T lymphocyte immunotherapy against tumor antigens after allogeneic HSCT. 
 
Another cell that plays an important role in the GvT effect is the NK cell. Due to the 
‘missing self ’hypothesis they are inhibited to act directly against class I MHC 
molecules on target cells.236 In murine studies, it was shown that NK cells had the 
capacity to migrate to the tumor, infiltrate and selectively kill tumor cells without 
killing normal cells. In a mHag mismatched mouse allotransplant model, immunization 
against leukemia or fibrosarcoma resulted in anti-tumor responses without the 
development of GvHD.237 In a recent study, NK cell-mediated GvHD reduction was 
demonstrated, where donor NK cells inhibited and lysed donor T lymphocytes 
activated during the initiation of GvHD.238 
 
In human studies, after allogeneic HSCT, donor NK cells may target malignant cells if 
the patients lack KIR that recognizes class I HLA allele groups that are present in the 
donor.239 NK cell alloreactivity could induce the GvL effect in patients with AML in 
both haploidentical240-242 and HLA-matched243-245 allogeneic settings with T cell 
depleted HSCT. The alloreactivity of the NK cells was demonstrated when the patients 
lacked the HLA-ligand for the donor-inhibitory KIR. However, this was not found in 
patients with acute lymphoid leukemia and CML.246 Furthermore, the NK cell 
alloreactivity did not work either in allogeneic HSCT without T cell depletion. This 
may be explained by two studies showing that T lymphocytes in the graft alter KIR 
expression on NK cells247 and Treg suppress cytotoxicity of the NK cells.248    
One in vitro study showed NK alloreactivity against melanoma and renal cell cancer 
cell lines by lysing the tumor cells in human KIR-ligand mismatch setting.249         
Recently, our group reported a safety analysis of donor-derived long-term ex vivo-
expanded human NK and NKT cells given as DLI to four patients with different solid 
tumors.250 Infusion of these cells did not cause acute GvHD or other severe side effects. 
One patient with hepatocellular cancer had decreased α-fetoprotein levels in serum 
following NK/NKT cell infusions suggesting a possible GvT effect.  
 
Clinical results of studies of the allogeneic GvT effect in patients with different solid 
tumors (such as renal cell, breast, colon, ovarian, pancreatic and advanced primary liver 
cancer) achieved until today will be highlighted below. 
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The first allogeneic GvT effect on metastatic renal cell cancer was reported by Childs et 
al112, observing a tumor response rate of 53% in 19 patients studied.113 Regression of 
metastases was delayed occurring at a median of 129 days after transplantation. Since 
the first report by Childs et al, several studies were performed with different 
conditioning regimens and immunosuppression treatments against GvHD.114-124 In all 
but two of these studies, GvT effect was reported with variable tumor response rates 
between 8% and 57%.114, 115, 117-123 In the two studies by Pedrazzoli et al and Rini et al, 
the absence of tumor response was due to the lack of adoptive immunotherapy (DLI) 
following HSCT124 and that patients with low performance status were enrolled in the 
study.116  
The largest series of allogeneic HSCT in patients with renal cell cancer was reported in 
a European multicenter trial including 124 patients from 21 centers.126 The tumor 
response rate was 32% and regression of metastases occurred at a median of 150 days 
after HSCT. Best overall survival of 70% at 2-years was seen in patients who had less 
than three metastatic sites, received DLI and developed chronic GvHD.   
 
Allogeneic HSCT with non-myeloablative conditioning in metastatic breast cancer 
exhibited tumor response rates between 16% and 37%.115, 118, 120, 128, 129 In the study by 
Bishop et al, the GvT effect was achieved by depletion of allogeneic T lymphocytes 
from the graft.128 After allogeneic HSCT these lymphocytes were administered at 
escalating doses to the patients. The tumor response rate was 33% and tumor regression 
occurred concomitantly with the development of GvHD. Carella et al used another 
strategy to enhance the GvT effect and decrease the non-relapse mortality, namely to 
administer high-dose chemotherapy with autologous graft before allogeneic HSCT.129 
The tumor response rate was 24% and no non-relapse mortality was noted during the 
first 100 days.  
The largest series of allogeneic HSCT in patients with breast cancer was reported from 
15 centers including 66 patients.130 Myeloablative conditioning regimen was used in 
59% of patients, whereas 41% received RIC. In the RIC group, more patients had poor 
pretransplant performance status (63% vs 26%). The tumor response rate was 31% in 
the myeloablative group and 29% in the RIC group. Patients who developed acute 
GvHD after RIC regimen had lower risk of relapse or progression than those who did 
not. Progression-free survival at 1-year was 23% with myeloablative conditioning and 
8% with RIC.   
    
Allogeneic HSCT in metastatic colon cancer has also demonstrated the existence of a 
GvT effect. Hentschke et al reported six patients transplanted with advanced disease, 
where regression of metastases was seen in one patient and another one had mixed 
response.117 The patient with mixed response had regression of lung metastases but 
progression of metastases in the liver. In the study by Kojima et al, four patients were 
treated and one patient achieved partial response and the others stable disease.132 
Carnevale-Schianca et al reported 15 patients, where one patient had partial response 
and three had stable disease.133  
The largest series of allogeneic HSCT in patients with colorectal cancer was reported 
from nine European centers including 39 patients.134 The tumor response rate was 46% 
and regression of metastases occurred at a median of 90 days after HSCT. Tumor 
regression occurred concomitantly with the development of GvHD and was achieved in 
59% of patients who experienced either acute or chronic GvHD.  
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The GvT effect was also demonstrated in patients with ovarian cancer.120, 136, 137 Bay et 
al presented five patients who had undergone allogeneic HSCT and four patients had 
tumor regression associated with the development of GvHD.136 In the study by Blaise 
et al, five patients were treated and three patients had a tumor response.120 
The largest series of allogeneic HSCT in patients with ovarian cancer was reported 
from six European centers including 30 patients.137 The tumor response was 50% and 
three patients had tumor regression in correlation to the development of acute GvHD. 
The median overall survival was 10.4 months. Patients who developed chronic GvHD 
had a better overall survival compared to those who did not (17.6 months vs 6.5 
months).  
 
Patients with unresectable metastatic pancreatic cancer have also undergone allogeneic 
HSCT.140-142 Takahashi et al reported five patients transplanted and two patients had 
tumor regression, whereas another two had decreased levels of the tumor markers CEA 
and CA19-9 in the serum.140 In the study by Kanda et al, seven patients were treated 
and tumor response was observed in two patients and another had decreased levels of 
CA19-9 in the serum.141 
The largest series of allogeneic HSCT in patients with unresectable pancreatic cancer 
was reported from three Japanese centers including 22 patients.142 The tumor response 
rate was 23% and the median survival was 139 days. Patients who developed chronic 
GvHD tended to survive longer than those who did not. 
At our center, two patients with resectable pancreatic cancer without metastasis 
underwent allogeneic HSCT with HLA-identical sibling donors in 2007. These two 
patients are alive, and with no sign of disease recurrence, three years after HSCT 
compared with the five control patients who all have died from their disease 
(unpublished data).  
 
Combined orthotopic liver transplantation and allogeneic HSCT for advanced primary 
liver cancer is only performed at our center in Sweden. Five patients with non-
resectable primary liver tumor have undergone orthotopic liver transplantation and 
were treated with allogeneic HSCT with non-myeloablative (low intensity 
conditioning) regimen.138 In two patients, no recurrence of the disease was observed at 
a follow-up of 10 and 26 months. In two patients, no engraftment of donor stem cells 
was seen, whereas one rejected the graft 2 months after HSCT. In two of the patients, a 
stable mixed donor chimerism was established.  
 
In conclusion, the existence a GvT effect against renal cell, breast, colon, ovarian, 
pancreatic and advanced primary liver cancer is suggested by the presented results. 
However, the use of allogeneic HSCT for solid tumors has been decreasing during the 
past years. One reason is the introduction of tyrosine protein kinases and kinase 
enzymes based medical therapies. Another reason is that the transplantation-related 
mortality is still high due to the patients´ physical condition to manage the 
transplantation. The allogeneic HSCT is therefore most successful in patients with low 
tumor load and good physical condition as reported by Barkholt et al.126  
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Inhibition or blockade of tyrosine kinases has increased survival in patients with poor 
prognosis251 or doubled the progression-free survival in pretreated patients with renal 
cell cancer.252 In patients with colon cancer treatment with antibodies against vascular 
endothelial growth factor (VEGF) or epidermal growth factor receptor (EGFR) have 
improved prognosis and have increased the median survival to 2 years.253, 254 Inhibition 
of VEGF or VEGF-signaling pathway by bevacizumab, or sunitinib or sorafenib has 
also produced anti-tumor responses in patients with renal cell cancer.252, 255, 256    
 
Finally, allogeneic HSCT would be improved even more in the future, if adoptive 
immunotherapies combined with new therapeutic drugs could be applied often in a 
stepwise space-rocket type of approach in order to reduce the tumor load. More specific 
adoptive immunotherapies that include genetic manipulation of donor lymphocytes as 
retroviral transfer of suicide genes and transfer of tumor-specific CTL against TAA, 
mHag or viral peptides, may also be promising strategies.   
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3 AIMS 
 
The general aim of this thesis was to investigate the anti-tumor or GVT effect after 
allogeneic HSCT in patients with different type of solid tumors.  
 
Specific aims were as follows: 
 
• To study inflammatory and anti-inflammatory cytokine response in patients 
after HSCT and to find a correlation between cytokine levels and anti-tumor 
response (paper I) 
 
• To determine the risk factors for complications in patients undergoing HSCT 
with low intensity as compared to reduced intensity conditioning regimen 
(paper II) 
 
• To explore if measurement of cytokine secretion during DLI given to patients 
after HSCT correlates with anti-tumor response (paper III) 
 
• To develop new methods for in vitro activation, detection and identification of 
tumor-reactive T lymphocytes from a patient with pancreatic squamous cell  
carcinoma as well as from an HLA-identical sibling (paper IV) 
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4 MATERIALS AND METHODS 
 
Patients included in the first three studies for this thesis were transplanted at Karolinska 
University Hospital Huddinge between 1999 and 2006. Patient characteristics are 
summarized in Table 1. 
 
 
4.1 BLOOD SAMPLES AND PREPARATION OF MONONUCLEAR CELLS 
 
In paper I, III and IV in this thesis, peripheral blood samples were used as starting 
material. In paper I, blood samples were collected within 1 month before and 1, 3, 6, 9 
and 12 months after SCT. At these time points, the patients were at the hospital for 
clinical check-ups and collecting blood samples at the same time was suitable. Blood 
sample collection is a non painful procedure for the patients and it is an easy and fast 
way to isolate mononuclear cells (MNC) or prepare serum.  
In paper III, blood samples were collected on one occasion from controls, and just 
before DLI as well as 1 and 3 weeks after DLI, from patients. The blood samples were 
centrifuged and MNC were isolated by Lymphoprep (Axis-Shield PoC As, Oslo, 
Norway) gradient centrifugation.  
In paper IV, blood samples were collected from a patient with pancreatic squamous cell 
carcinoma and an HLA-identical sibling. 
 
 
4.1.1 ELISA and ELISpot analyses  
  
For extracellular cytokine detection we used two different methods: enzyme-linked 
immunosorbent assay (ELISA) and enzyme-linked immunospot (ELISpot) techniques.  
 
The ELISA technique measures secreted protein (cytokine) in body fluids or 
supernatants from different cell cultures. The disadvantage of the assay is the 
intervention of soluble cytokine receptors and inhibitors and the degradation of 
proteins. Cytokines are mainly produced locally, for that reason the detection of 
cytokines in serum may sometimes be a rough method. However, when systemic levels 
are identified, it reflects a strong reaction and some interesting correlations have been 
revealed.     
 
In paper I, we used commercially available assays, i.e. automated chemiluminescence 
immunoassay (Immulite, DPC, Los Angeles, CA) for analyzing TNF-α and IL-10 and 
Quantikine ELISA kits (Quantikine R and D Systems, Minneapolis, Minn) for IFN-γ 
and TGF-β1 detection.  
     
The highly sensitive ELISpot assay detects cells that actively secrete cytokines 
reflecting in vivo immune responses at single cell level. The disadvantage of the assay 
is that one cannot determine the phenotype of the cells since the cells are washed away 
during the procedure. However, this problem can be overcome if the studied cell 
populations are purified. 
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Paper   I II III 
Time period of study  2000-2002 1999-2004 2001-2006 
Number of patients  6 48 8 
Males/Females  4/2 33/15 7/1 
Recipient age, range   47-66 28-77 35-67 
Diagnosis    
  AML   0 0 3 
  MPS   0 0 1 
  Renal cell carcinoma  4 17 1 
  Colorectal carcinoma  2 15 2 
  Primary liver carcinoma  0 11 0 
  Prostate carcinoma  0 2 1 
  Other solid tumors  0 3 0 
Donors    
  HLA-identical sibling  3 25 1 
  MUD   3 23 7 
Conditioning    
  Bu+Cy   0 0 1 
  Flu+Bu   0 0 2 
  Flu+Melphalan  0 0 1 
  Flu+TBI   5 23 0 
  Flu+Cy   1 25 4 
Graft source    
  PBMC   6 46 8 
  BM   0 2 0 
GvHD prophylaxis    
  CsA+MMF   5 19 0 
  CsA+MTX   1 21 8 
  Tacrolimus+MMF  0 3 0 
  Tacrolimus+MTX  0 5 0 
GvHD    
  acute 0   2 12 1 
  acute I-II   2 29 5 
  acute III-IV   2 7 2 
  chronic 0   3 37 6 
  chronic limited   3 11 2 
DLI    
  Number of patients  5 31 8 
  Number of DLI, range  1-5 1-11* 1-5 
* including infusions of ex vivo expanded mixed donor NK/NKT cells    
 
Table 1. Patient characteristics. 
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This assay has been shown to have both a sensitivity and specificity of up to 200 times 
greater than conventional ELISA by enumerating dynamically the number of cytokine 
secreting cells both at basal level and after specific antigen stimulation.257  
 
In paper III, PHA-stimulated MNC were analyzed by ELISpot assay for the cytokines 
TNF-α, IFN-γ, IL-4, IL-10, IL-12 and IL-13 (Mabtech AB, Stockholm, Sweden). All 
samples were tested in duplicates. One advantage of the analysis is that the cytokine 
secretion was evaluated by a single person. The ELISpot software counts the number of 
spots or spot forming cells (SFC) where each spot represents a single cytokine 
producing cell.  
 
 
4.1.2 Flow-cytometric Assay of Specific Cell-mediated Immune 
response in Activated whole blood   
 
 
Flow-cytometric assay of specific cell-mediated immune response in activated whole 
blood (FASCIA) analysis has been developed for the detection of specific immunity 
against several antigens.258, 259 For example, VZV specific immunity in children has 
been studied with FASCIA.260 In the study by Svahn et al, diluted whole blood was 
incubated with VZV-antigen and activated immune cells (T lymphocytes) against VZV 
were visualized by the identification of lymphoblasts displayed as large granular 
lymphocytes by their scatter profile using flow cytometry. So far, FASCIA has only 
been used to detect immunity against infectious agents, and the methodology has been 
based on peptide and/or protein antigens.  
 
The advantage of using FASCIA assay as compared to other methods of T lymphocyte 
activation is that the FASCIA assay requires only small amounts of blood and little 
time and labours and can thus be readily carried out on single samples as well as for 
large-scale studies.260 The use of whole blood samples without specific preparation of 
dendritic cells or cell separation saves a lot of time. Another advantage is the easy 
access to small volumes of blood where the cells experience an environment similar to 
that in vivo. The FASCIA technique also gives the possibility to a more sensitive read-
out than mixed lymphocyte reaction, and can be considered as an enhanced mixed 
lymphocyte reaction. In paper IV, we have used the FASCIA technology with patient-
derived tumor cells as targets and activated T lymphocytes as read-out.  
 
Diluted whole blood samples and the patient’s apoptotic/necrotic (apo-nec) tumor cells 
(discussed later) or irradiated MNC were examined by FASCIA for CD3+, CD4+, 
CD8+ cells and for the activation marker CD25 (Figure 2). Following FASCIA, 
CD4+CD25+ and CD8+CD25+ cells from the patient and his HLA-identical sibling 
were sorted with FACSAria (BD Biosciences, San José, CA) and analysed using 
FACSDiva software (BD Biosciences).  
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Patient blood sample
Dilution 1:10 
(RPMI)
1 x 106 cells
Primary culture of 
pancreatic tumor
2.5 x 104 tumor cells
Activated T cells
CD4+CD25+
CD8+CD25+ 
Lymfopreparation, 
irradiation (20 Gy)
2.5 x 104 MNC
Donor blood sample
Dilution 
1:10 
(RPMI)
1 x 106 cells
Flow-cytometric Assay of Specific Cell-mediated Immune responses in 
Activated whole blood (FASCIA)  
Irradiation 
(100 Gy)
 
 
 
Figure 2. Schematic description of the FASCIA procedure. 
 
 
 
4.2 PRIMARY CULTURE OF TUMOR CELLS 
 
In paper IV, fresh pancreatic cancer tissue was obtained from a patient with pancreatic 
squamous cell carcinoma undergoing pancreatic resection surgery ad modum Whipple. 
After surgical resection, the malignant phenotype of the tumor was assessed using light 
microscopy. The tumor represented a squamous epithelial cell malignancy using 
staining with hematoxyline-eosin demonstrating morphology of squamous cell 
carcinoma. Immunohistochemical staining showed that the cells were negative for 
neuroendocrine tumor markers chromogranin A and synaptophysin, thereby 
neuroendocrine tumor origin was excluded.  
 
After enzymatical digestion of the tumor, tumor cells were incubated and cultured. The 
initial growth rate was slow. After 3 weeks of incubation and feeding which comprised 
change of culture medium twice weekly, the tumor cells began to grow and on day 43 
these cells were split the first time by trypsinization. Following trypsinization, which 
removed most stroma derived cell types, the remaining adherent malignant cells were 
left untouched in the culture flask except for regular media changes. After two months 
of culturing, the malignant cells had grown to confluency and the majority of the cells 
appeared to be of epithelial origin and had a malignant phenotype. The prolonged 
culture period was expected due to the slow growth of the primary tumor and as a 
consequence of removal of contaminating stromal cells.  
 
The malignant cells demonstrated varying morphology where the majority of the cells 
had small and round nuclei with clearly visible nucleolis. Multinuclear cells as well as 
elongated “spindle” shaped cells, possibly representing motile forms, could be observed 
in the cell culture (Figure 3). 
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Apo-nec tumor cells were prepared from the patient’s tumor cells slightly modified as 
described by von Euw et al.261 After gamma irradiation at 100 Gray, the tumor cells 
were plated onto small culture flasks and incubated for 48 hours to complete the 
apoptotic process. To confirm that the tumor cells had become apoptotic and necrotic, 
Annexin V and Propidium iodide binding (Annexin V-FITC Apoptosis Detection Kit, 
BD Biosciences) and flow cytometric analysis were performed.      
 
 
A B
 
 
 
Figure 3. Primary culture of tumor cells from a patient with pancreatic squamous cell carcinoma. 
The figure show tumor cells from the patient at 36 (A) and 62 (B) days, respectively.  
 
       
 
4.3 CDR3 SIZE SPECTRATYPING  
 
CDR3 size spectratyping is based on amplification of 24 TCR Vβ genes and 
characterizes the relative usage of each Vβ gene subfamily and also identifies clonal T 
lymphocyte populations within each subfamily.262   
 
This method is sensitive and has the advantage to cover the entire Vβ repertoire as well 
as to detect changes in T lymphocyte repertoire that can not be performed with flow 
cytometric analysis. It can be applied for interpretation and identification of clonal T 
lymphocyte populations responsible for clinical in vivo reactions such as GvL/GvT 
effect and GvHD. The main disadvantage of the method is that it does not reveal the 
functional specificity of the T lymphocyte clones.  
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In paper IV, RNA from flow cytometry sorted cells from the patient and his HLA-
identical sibling was prepared using the commercially available QIAmp RNA Blood 
Mini Kit (QIAGEN, Hilden, Germany). cDNA was synthesized from RNA using the 
high-capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA).  
After cDNA synthesis, reverse transcription (RT)-PCR was performed to amplify the 
CDR3 of the TCR. A set of 28 Vβ-specific primers spanning all 24 TCR Vβ 
subfamilies were amplified by a constant 5’-end primer labelled with 6-fluorescein 
phosphor amidite (6-FAM).263  
 
The size distribution of each PCR product was analyzed using capillary electrophoresis 
on an ABI 3130 Genetic Analyzer (Applied Biosystems) allowing one base pair 
resolution. The fluorescence intensity of each band was quantified with the Peak 
Scanner Program (Applied Biosystems) and translated into a histogram displaying the 
length and intensity of each CDR3 fragment.  
 
              
4.4 RESPONSE EVALUATION CRITERIA IN SOLID TUMORS 
 
In patients with solid tumors, the tumor load was examined by computer tomography 
(CT) of the thorax and abdomen before SCT, and following every third month after 
SCT (paper I, II and III). Evaluation of tumor response was based on the international 
response evaluation criteria in solid tumors (RECIST).264  
 
In paper II, RECIST was not applicable in patients with advanced primary liver cancer 
because of the lack of pre-transplant metastases. Therefore, these patients were 
evaluated using clinical parameters based on the results of CT (thorax and abdomen), 
bone scans and magnetic resonance imaging of liver, bile ducts, and pancreas 
performed according to the same time schedule after SCT as for the other solid tumor 
patients, or autopsy examinations.  
 
In paper I, examination of tumor load was also evaluated based on our local method. 
We used the combined results of CT and autopsy examinations showing a decrease in 
size and/or number of metastases. Regression, progressive and stable disease were 
defined separately for each metastatic localization (lung tissue, pleura, lymph nodes 
and liver). Furthermore, an assessment of the total metastatic load was performed, 
defined as mixed response, stable disease and progressive disease. Each CT 
examination was compared with the closest preceding CT examination. 
 
There are both advantages and disadvantages with RECIST and our local method, 
respectively. One disadvantage of RECIST is the possibility to choose between the 
evaluation of target lesions or evaluation of both target and non-target lesions (i.e., the 
best overall response). Another disadvantage with RECIST is the choice of the five 
largest metastases per organ (and ten largest in total), which implies that smaller 
metastases in other organs are missed. Therefore, in some patients, the evaluation of the 
largest target lesions may occur only in one organ, thereby failing to detect the changes 
of other metastases. In contrast, our local method includes four main metastatic 
localizations independent of their initial size. Furthermore, an appearance of a new 
metastasis independently of the organ localization will be evaluated as progressive 
disease using RECIST, despite the regression of other metastases in the same or other 
organs. One disadvantage of our local method is that mixed response in some cases was 
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classified as tumor regression, i.e. despite the fact that progression was not totally 
absent in the patient. However, our evaluation method reflects the dynamics of the 
metastases over time because it compares the changes with the previous CT 
examination instead of the one which was performed pretransplantation as is done 
according to RECIST.    
 
RECIST has been developed within oncology where it was mainly used after chemo 
radiotherapy. This therapy initiates cell necrosis of metastases whereas immunological 
cell therapy triggers inflammation in the tumor. The inflammation appears as increased 
tumor size or volume estimated with radiological examinations, which is misleading 
since this will be classified as tumor progression with RECIST. Immunological cell 
therapy is therefore preferably evaluated when the inflammation has disappeared and 
the apoptotic/necrotic tumor cells appear as stable disease or regression of the 
metastases.  
 
 
4.5 STATISTICAL ANALYSES  
 
In paper I, the two-sided Fisher exact-test was used to compare the cytokine balance to 
tumor response.  
 
In paper II, the probability of overall survival was calculated according to the Kaplan 
and Meier method. Time to transplantation-related death, response, acute GvHD, and 
chronic GvHD were estimated using a non-parametric estimator of cumulative 
incidence curves. Competing events for transplant-related mortality were death in 
progressive disease for response, death without response, and death without GvHD. 
Patients were evaluated for tumor response and chronic GvHD if they survived more 
than three months. The differences between numbers of days to complete donor 
chimerism in T and B cells were compared using the Mann-Whitney U test. Analyses 
were performed using the cmprsk package (developed by Gray, June 2001), Splus 6.2 
software, and Statistica software (Statsoft Inc, Tulsa, OK, USA). A p-value <0.05 was 
considered statistically significant. 
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5 RESULTS AND DISCUSSION 
 
Allogeneic HSCT using non-myeloablative conditioning has been explored as 
immunotherapy against progressive disease in patients with different solid tumors. In 
the beginning of the SCT era, it has become clear that the transplanted immune cells 
were capable of eradicating tumor cells. This immunological anti-tumor effect or GvT 
effect has been studied by several groups with slightly varying results. This is most 
likely due to the different conditioning types, immunosuppression strategies and last 
but not least, differences in the patients underlying disease. The anti-tumor effect may 
be strengthened by DLI from the same stem cell donor when tumor progression 
threatens or mixed chimerism appears. DLI may also contribute to GvHD. The risk of 
GvHD may be reduced using escalating doses of DLI. However, it seems that donor T 
lymphocytes mediate both GvHD and GvT effect since the risk of tumor recurrence is 
higher when the donor T lymphocytes are depleted from the graft. Therefore, a patient 
having mild acute and/or chronic GvHD has potentially a high chance of the GvT 
effect.     
 
In the first three studies of this thesis, we investigated the anti-tumor effect in patients 
with different solid tumors undergoing HSCT. More specifically, in paper I and III, the 
anti-tumor effect in connection to cytokine release was examined. In paper II, we 
studied the outcomes after HSCT and reported the most favorable tumor response and 
the best anti-tumor effect. In paper IV, we showed that it was possible to detect and 
identify tumor-reactive T lymphocytes from an HLA-identical sibling against tumor 
cells from a patient with pancreatic squamous cell carcinoma. 
 
 
5.1 THE RELATION BETWEEN GVT EFFECT AND CYTOKINE RELEASE 
AFTER HSCT (PAPER I AND III) 
 
Previous studies from our group have revealed allogeneic GvT effect in patients with 
metastatic colon and renal cell carcinoma.117, 131 Hentschke et al reported disparate 
responses of metastases in one patient with colon and two patients with renal cell 
carcinoma, who had regression of lung metastases but progression of metastasis in the 
liver.117 Another study in our group showed higher levels of TNF-α, IFN-γ and IL-10, 
but lower levels of TGF-β1 in patients with myeloid leukemia who developed acute 
GvHD II-IV two weeks after SCT in contrast to those with no or mild GvHD.39  
 
These results prompted us to examine whether there is a correlation between cytokine 
release and tumor response in patients with different solid tumors. In paper I, we found 
a correlation between the two inflammatory cytokines TNF-α and IFN-γ and tumor 
regression in contrast to the two anti-inflammatory ones IL-10 and TGF-β1 which 
correlated with disease progression. In paper III, we reported a higher expression of 
TNF-α, IFN-γ, IL-12 (another inflammatory cytokine) and IL-10 in patients with tumor 
regression in contrast to those with disease progression during DLI therapy.   
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Mild acute GvHD grade I-II and chronic GvHD have been associated with the 
GvL/GvT effect resulting in leukemic/tumor cell regression126, 219, whereas severe acute 
GvHD can lead to transplantation related complications. Secretion of the inflammatory 
cytokines TNF-α and IFN-γ in serum has been reported during the conditioning before 
SCT and the development of acute GvHD.37, 39, 45 Antigen presenting cells of the host 
may activate donor T cells of the graft, thereby enhancing this inflammatory cytokine 
production.  
 
Previous studies reported high levels of TNF-α in serum and increased TNF-α and IFN-
γ producing MNC in patients with hematological malignancies who developed acute 
GvHD grade I-IV.40, 52 Similarly, increased TNF-α and IFN-γ levels in serum were 
found in three of our six patients in association with conditioning and acute GvHD 
early after SCT. Furthermore, in our patients, who were diagnosed with acute grade II-
III and chronic GvHD after DLI, also high expression of TNF-α and IFN-γ in MNC 
was found during DLI followed by tumor regression. However, in another study 
decreased IFN-γ producing MNC was reported in patients with hematological 
malignancies who had grade 0-I acute GvHD.50 
Since severe acute GvHD grade III-IV is associated with transplantation related 
complications, more thorough analyses for cytokines in two patient groups, acute 
GvHD grade I-II and grade III-IV, would be advantageous in order to be able to predict 
the outcome of DLI administration with escalating doses.    
 
IFN-γ may contribute to an anti-tumor effect by stimulating an immune response since 
it can up-regulate MHC class I expression on tumor cells.265 Thus, an increased tumor 
development mediated by IFN-γ deficiency may occur because of diminished control of 
target cell growth and apoptosis. High TNF-α and IFN-γ levels in serum found toward 
the end of the first year after SCT and secretion from MNC found in our studies during 
DLI therapy may contribute to the GvT effect and are in line with observations in other 
human studies. Increased expression of IFN-γ in T cells has been reported in patients 
with CML who achieved clinical remission after DLI.266 In contrast, decreased IFN-γ in 
MNC has been found in patients with hematological malignancies who relapsed 
compared to those with no signs of relapse.51 DLI containing T cells may contribute to 
an anti-tumor effect by enhanced IFN-γ production as was seen in some of our patients 
who showed regression of metastases after DLI. 
 
IL-10 was first described as an anti-inflammatory cytokine, but recent studies have 
shown that in some cases it acts as an inflammatory one.267 In some studies 
immunosuppressive activities were observed as expected, while in others IL-10 
augmented immune or inflammatory responses. The results regarding the levels of IL-
10 in serum after transplantation and their correlation to the incidence of GvHD are 
inconsistent. In some studies increased levels of IL-10 after HSCT have been related to 
low occurrence of acute GvHD.268, 269 In other studies high levels of IL-10 have been 
noted before or during acute GvHD.39, 40, 65, 66, 270-273  
 
Furthermore, the functional role of IL-10 producing cells in protective immunity has 
also been demonstrated in kidney274 and pancreatic islet275 transplant patients. The ratio 
of IFN-γ/IL-10 differed between non-rejecting and rejecting transplant patients. Low 
ratio due to high IL-10 secretion was found in patients with stable graft function.274, 275 
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In our study, high expression of IL-10 in MNC before DLI in patients with favorable 
outcome of disease response seemed to discern those patients who did not respond with 
low IL-10 secretion just before DLI. However, Schulz et al reported high circulating 
levels of IL-10 in patients who failed to respond to DLI, suggesting moderation of the 
immune system and thereby allowing the leukemic progression.276 In our study, 
patients with disease progression showed temporarily increased IL-10 expression in 
MNC in the samples obtained between each DLI. Thus, IL-10 might have suppressed 
the cytotoxic effect of donor lymphocytes against leukemic/tumor cells.    
 
The major biological function of IL-10 is to combat inflammatory responses267 and it is 
therefore difficult to decide whether IL-10 observed during an inflammatory response 
such as acute GvHD or GvT effect is due to the response or is secreted as a regulatory 
mechanism. In the future, we may envisage studies where IL-10 acts in synergy 
together with inflammatory cytokines supporting immune or inflammatory responses 
e.g., GvT effect following allogeneic HSCT.                             
 
IL-12 is a potent immunostimulatory cytokine and an inducer of Th1 cell activity and 
IFN-γ production. IL-12 has been reported to play an important role in acute GvHD and 
GvL effect. High levels of IL-12 in plasma were associated with the development of 
acute GvHD grade II-IV72 and with the GvL effect without increasing the risk for 
GvHD.73 In our study, high expression of IL-12 in MNC was found in patients with 
disease response, supporting the anti-tumor effect of this cytokine.       
 
Whether increasing number of infused CD3+ T cells using escalating doses of DLI 
does influence the balance of inflammatory/anti-inflammatory cytokines needs to be 
further studied in larger patient groups to determine optimal timing and setting of DLI 
administration.    
 
Based on our studies, patients seemed to benefit from DLI therapy, (i.e., tumor 
regression) when their MNC have high capacity to produce IL-10 and the inflammatory 
cytokines TNF-α, IFN-γ and IL-12. Measurement of the kinetics of these cytokines 
could predict how the immune response develops after allogeneic SCT. Monitoring 
these cytokines before administration of DLI could also predict those patients who will 
respond to DLI therapy. In the future, this monitoring might be useful for directing 
infusion of donor lymphocytes or NK cells or adoptively transferred tumor specific T 
cells of stem cell donor origin to intensify the GvT effect after allogeneic SCT against 
solid cancer.   
 
5.2 OUTCOMES AFTER HSCT (PAPER II) 
 
In 1999, when our centre started with allogeneic HSCT for patients with solid tumors, 
different non-myeloablative protocols were already in use for patients with 
hematological malignancies and also to some extent at other centers for patients with 
solid tumors. Our centre decided to utilize a low intensity conditioning with only 2 Gy 
TBI and Flu together with the immunosuppressive drugs CsA and MMF. However, in 
2001, the high risk of graft rejection prompted us to replace TBI by Cy, thus RIC with 
Flu and Cy was in use. 
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Non-myeloablative treatment is suitable for patients with solid tumors since the main 
emphasis is not to eradicate the hematopoietic cells in the bone marrow, as it is the case 
with myeloablative treatment for hematological malignancies. This treatment may also 
be effective for patients with solid tumors older than 50 years, which is the common 
age, since they could tolerate a transplant better if organ impairment is a difficulty.  
In this study, we report the outcomes after HSCT based on six years of experience in 48 
patients with different solid tumors such as renal cell, colorectal, prostate and advanced 
primary liver cancer, applying low or reduced intensity conditioning. 
 
There were equal numbers of patients in the two conditioning groups. The age of the 
donors was lower for patients treated with RIC, which could be explained by a larger 
proportion of unrelated donors in this group. Because solid tumor patients are often 
elderly, theirs siblings are also elderly, whereas donor registries worldwide have 
younger unrelated donors. 
 
Even though, rejection of stem cells occurred in double as many patients in the low 
intensity group than in the RIC group, no significant difference was found between the 
two conditioning groups. Our centre uses chimerism analysis of CD3+ cells to define 
rejection. To better predict rejection, NK cells may also play an important role in 
chimerism analysis. Less than 50% of donor T and NK cells on day 14 after HSCT has 
indicated an increased risk for rejection in patients given low intensity conditioning.277    
 
Patients receiving low intensity conditioning had a shorter neutropenic phase and 
earlier development of donor B cell chimerism than patients treated with RIC. 
Hematopoietic growth factors such as G-CSF have been used after HSCT to accelerate 
myeloid recovery and shorten the high risk period of bone marrow aplasia.278 
Therefore, patients in the low intensity conditioning group were treated with G-CSF 
after HSCT which may explain the shorter time to neutrophil engraftment.279-281 Thus, 
our finding of higher number of G-CSF-treated patients in the low intensity group was 
expected since our previous findings of a higher occurrence of acute GvHD grade II-IV 
in patients with hematological malignancies.279, 282 This result encouraged us to 
discontinue G-CSF treatment in patients receiving RIC. However, in this study, we did 
not find an increased risk of acute GvHD in patients who were treated with G-CSF. The 
use of G-CSF might also explain the incidence of fewer bacterial infections in the low 
intensity conditioning group, even though the difference in the two conditioning groups 
was not significant.  
 
The trend to increased risk of bacterial infections in the RIC group could be explained 
by a stronger effect of Cy and prolonged Flu treatment that may have caused more 
effective suppression of the patients’ immunocompetent cells as compared to the low 
intensity group. 
                       
There was no significant difference in the incidence of tumor response between the two 
conditioning groups. Patients with advanced primary liver cancer had the most 
favorable tumor response compared to all other tumor types (70% vs. 32%).    
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Furthermore, tumor response was more common in patients receiving adjuvant cell 
infusions, i.e. DLI or NK/NKT cells, and who developed chronic GvHD either before 
or after the cell infusions, in the absence of an association with the type of conditioning 
(75% vs. 34% of all other patients). This was also demonstrated in a larger patient 
group with renal cell cancer.126 The effect of DLI and GvHD seems to support the 
allogeneic GvT effect which has been shown to be associated with CD8+ T cells in 
patients with renal cell cancer.46, 283  
 
Considering these results, we suggest that T and NK/NKT cell functions of DLI may 
trigger the development of chronic GvHD. This would induce an inflammatory 
cytokine and chemokine response, supporting the migration of donor lymphocytes 
towards tumor cells. In this way infusion of donors’ NK/NKT cells would be a valuable 
alternative to DLI. In this study, four patients in the RIC group received ex vivo long-
term expanded NK/NKT cells from the stem cell donor. None of the patients developed 
acute GvHD after the cell infusions as reported in more detail by our group.250 
Furthermore, no significant difference was found in the incidence of severe acute 
GvHD grade III-IV after DLI between the two conditioning groups. However, 32% of 
patients in the RIC group developed acute GvHD grade II after DLI compared to none 
of the patients receiving low intensity conditioning. This may imply that acute GvHD 
grade II is desirable for the allogeneic GvT effect in patients with solid tumors, 
reflecting the tendency towards prolonged survival in patients given RIC.       
 
A tendency for prolonged overall survival was found in the RIC group compared to the 
low intensity conditioning one (30% vs. 17% at 2-years). Patients with advanced 
primary liver cancer had the longest overall survival which might be due to the fact that 
these patients are younger (median 48 years) than patients with renal cell (median 58 
years) and colorectal cancer (median 60 years). However, the overall survival for 
patients with renal cell and colorectal cancer was longer than that achieved with even 
the most modern combinations of oncological treatments for metastatic disease. The 
transplantation-related mortality rate was 65% in the low intensity conditioning group 
and 52% in the RIC group. Although progress has been made in the field of allogeneic 
HSCT for patients with solid tumors with a tendency for prolonged survival, the 
majority of patients, irrespective of tumor type, still die in progressive disease. Previous 
results on tumor response vary between 17-40% in patients with renal cell,113, 114, 126 
breast115, 118, 120 and ovarian cancer.136 However, in most studies only sibling donors 
were considered which implies that the conditioning regimens did not include 
antithymocyte globulin and caused less immunological imbalance.  
 
Since the major obstacle for HSCT in the treatment of patients with solid tumors is 
progression of the underlying disease, the results in this study could potentially be 
improved if patients with low tumor load and good physical condition are selected for 
HSCT. Allogeneic HSCT could be given only to patients with stable disease at the time 
of transplantation. In the future, there might be a possibility for infusion of donor-
derived immune or tumor-specific cells instead of DLI after SCT in patients with tumor 
progression to exert a stronger GvT effect.          
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5.3 TUMOR-REACTIVE T LYMPHOCYTES FOR PANCREATIC CANCER 
(PAPER IV)  
 
In this study, we detected and identified tumor-reactive T lymphocytes from an HLA-
identical sibling against tumor cells from a patient with pancreatic squamous cell 
carcinoma. Using the FASCIA technique we could activate T lymphocytes in whole 
blood from the HLA-identical sibling against patient-derived tumor cells, identify the 
phenotype and sort activated T lymphocytes based on their expression of activation 
markers. Using the CDR3 size spectratyping of TCR genes we could distinguish tumor-
reactive T lymphocytes from activated T lymphocytes against peripheral blood MNC 
from the patient. Using this method, previous studies have demonstrated the presence 
of T lymphocyte populations associated with GvT effect and GvHD.262, 284, 285 It has 
been shown that expansion of some clones within the TCR Vβ repertoire appeared 
early after DLI, and together with clinical responses this suggests that these clones 
mediate the GvL and GvT effect in patients with CML285 and multiple myeloma262, 
respectively. In the study by Orsini et al other T lymphocytes clones appeared at later 
time points when GvHD was developed. Michalek et al identified and monitored an 
alloreactive T lymphocyte clone associated with GvHD in a patient with AML.       
    
Based on the results of this study, we suggest that allogeneic HSCT should be applied 
to a larger extent for patients with pancreatic adenocarcinoma since these patients’ 
tumor load is limited. Furthermore, pancreatic adenocarcinoma is a solid cancer with 
poor prognosis where the only curative strategy is surgery. At the time of diagnosis the 
majority of patients have an advanced disease which is inoperable; therefore they 
cannot be offered a curative but rather a palliative treatment.286 Patients, who can be 
treated with surgery and who show no signs of remaining tumor, have an expected 5-
year survival of 10-25%.287 
Until today, three centres in Japan apply HSCT for patients with unresectable 
pancreatic adenocarcinoma using HLA-identical sibling donors.139-141 In one clinical 
trial they reported tumor response of 23% and median survival of 139 days on 22 
patients (15 patients with metastatic disease).142 At our centre, two patients with 
resectable pancreatic adenocarcinoma without metastasis underwent HSCT with HLA-
identical sibling donors in 2007. These two patients are alive, and with no signs of 
disease recurrence, three years after HSCT compared with the five control patients who 
all have died from their disease (unpublished data).        
  
Combining FASCIA and CDR3 size spectratyping might be a way to identify tumor-
specific T lymphocytes as well as to isolate and expand these cells for infusion of 
tumor-specific or leukemia-specific DLI to patients with tumor progression or disease 
relapse. The methods could be evaluated also for infection-specific DLI to cure viral 
and bacterial infections in transplanted patients with suppressed immune responses. 
Another approach would be to identify and deplete GvHD-specific T lymphocytes 
clones in patients with GvHD development.  
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In the future, there might be a possibility to enhance the GvT/GvL effect by in vitro 
expansion and infusion of anti-tumor/leukemic specific donor T lymphocytes from 
donors instead of ordinary DLI after SCT in transplanted patients with signs of tumor 
progression or disease relapse.  
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6 CONCLUSIONS 
 
 Dominating TNF-α and IFN-γ levels in serum correlates with tumor regression 
in patients with renal cell and colon cancer after allogeneic HSCT using our 
local method on examination of tumor load. 
 
 Increased expression of TNF-α, IFN-γ, IL-12 and IL-10 in MNC was found in 
patients with solid tumors and hematological malignancies with favorable 
outcome of disease response after DLI therapy. 
 
 In patients with different solid tumors receiving low intensity conditioning, 
engraftment and development of donor B cell chimerism occurred earlier than 
in patients given RIC. 
  
 Patients with advanced primary liver cancer who had previously undergone 
orthotopic liver transplantation had the most favorable tumor response. 
 
 The most favorable tumor response was more common in patients receiving    
DLI or NK/NKT cells, and who developed chronic GvHD either before or after 
the cell infusions.  
 
 A tendency for prolonged overall survival was found in patients receiving RIC 
compared to the low intensity conditioning group. 
 
 Tumor-reactive T lymphocytes from an HLA-identical sibling against tumor 
cells from a patient with pancreatic cancer could be detected and identified 
using FASCIA. Using CDR3 size spectratyping tumor-reactive T lymphocytes 
could be distinguished from T lymphocytes activated against peripheral blood 
MNC from the patient.  
 
These findings might give together with new strategies a better treatment for 
patients after allogeneic HSCT aiming at a more effective tumor response. For 
example, monitoring cytokines before adjuvant cell infusions could predict those 
patients who will gain from immunotherapy. Furthermore, combining FASCIA and 
CDR3 size spectratyping might be a way to identify, isolate, in vitro expand and 
infuse tumor/leukemia-specific T lymphocytes from stem cell donors in order to 
intensify the GvT/GvL effect when signs of tumor progression or disease relapse 
threaten.   
      
  44
7 FUTURE PERSPECTIVES 
 
Because donor T lymphocytes mediate both GvHD and GvT effect, the main goal in 
this field is to design methods where we can distinguish between the cells responsible 
for GvHD and those that mediate the GvT effect. Thus, suppression of GvHD with 
maintenance of GvT effect is a desirable outcome for clinical allogeneic HSCT.  
 
One way to achieve this would be co-transplantation of expanded natural CD4+CD25+ 
regulatory T lymphocytes (Treg) with donor T lymphocytes. In a murine study, it was 
shown that co-transplantation of these lymphocytes inhibited the development of 
GvHD while preserving the GvT effect.288 The authors claimed that massive 
proliferation of alloreactive T lymphocytes in the graft was inhibited by Treg, which 
was associated with the onset of GvHD without affecting their function. Thus, Treg 
could separate GvHD from GvT activity mediated by conventional donor T 
lymphocytes. The expansion of Treg was performed by stimulating CD4+CD25- T 
lymphocytes with IL-12 in the presence of Treg. The CD4+CD25- T lymphocytes 
proliferated and expanded while they expressed the activation marker CD25.  
 
Another way would be infusions of Th17 lymphocytes of donor origin instead of 
ordinary DLI to enhance the GvT effect. It has been shown that Th17 lymphocytes can 
promote anti-tumor immune responses indirectly through the recruitment of DC and 
cytotoxic effector cells and by promoting effector T and NK cells trafficking to, and 
retention within the tumor microinvironment (reviewed in Zou et al).18 
 
Another possible treatment to intensify the GvT effect may be the generation of 
specific CTL against viral peptides to treat solid tumors as reported by Takahashi et al, 
where the target antigen for CTL in renal cell cancer appeared to be a human 
endogenous retrovirus.140 
 
In the future, we may envisage generation, expansion and infusion of Th17 
lymphocytes or specific CTL against viral peptides to control tumor progression in 
order to intensify the GvT effect. Furthermore, co-transplantation of expanded Treg at 
the time of allogeneic HSCT may also contribute to a favorable tumor response.   
 
Finally, the use of FASCIA and CDR3 size spectratyping methods might be a way to 
identify tumor-specific donor CTL against different solid tumors as well as to isolate 
and expand these cells for infusion of tumor-specific or leukemia-specific DLI. These 
methods could be evaluated also for infection-specific DLI to cure viral and bacterial 
infections in transplanted patients with suppressed immune responses.      
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